Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
Regarding the onset of inflammatory bowel disease, it is important to reduce the diversity of intestinal microbiota. We generated the mice inoculated with healthy human feces (HC mice) or primary sclerosis cholangitis-associated ulcerative colitis (PSC / UC) patient feces (PSC/UC mice) and analysed a week after transplantation. In PSC / UC mice, Th17 cells was accumulated in liver compare to the HC mice. Next, we isolated 3 dominant microbiota in mesenteric lymph node of PSC/UC mice. Klebsiella pneumonia, Proteus mirabilis and Enterococcus gallinarum were isolated.We also analysed fecal microbiota in Healthy controls and PSC/UC patients. Analysis by the Q-PCR method confirmed that these intestinal bacteria were detected more frequently in PSC / UC patients than in HC control. We demonstrated that certain intestinal microbiota are involved in extraintestinal lesions. We will further promote vaccine therapy with the analysis of these bacteria.
|